The Company holds 16.15% of Psych Capital PLC, which is traded on the AQSE Growth Market.
Psych Capital is an incubation and investment firm that deploys early-stage capital whilst building or supporting new companies in Europe’s psychedelic science and healthcare industry. Psych Capital operates a leading business-to-business media and content industry data, insights, and networking platform, PSYCH, with over 20,000+ subscribers.
Psych Capital intends to identify, fund and support the building of future companies across three core pillars: therapeutic treatments, drug development, and data/artificial intelligence.
To date PSYCH Symposium events has offered over 80 speakers, including Professor David Nutt, Christian Angermayer and Rick Doblin, welcomed over 3,000+ delegates and generated strong revenue through sponsorship and ticket sales.
Psych Capital is also developing the Blossom Database pursuant to a third-party licensing arrangement, and Psych Capital will work to develop an artificial intelligence platform that will provide biotech companies with advanced clinical data that will be able to fast-track drug development and loop back the real-world data, in a centralized database, to provide feedback on molecules and associated therapy programmes.